The findings mean that scarring in the esophagus as a result of eosinophilic esophagitis (EoE) can be found earlier, allowing for more targeted intervention.
A recent study using a currently approved FDA gastrointestinal (GI) device showed it could also be used to clarify the level of early scarring in the esophagus of pediatric patients with eosinophilic esophagitis (EoE).
The Endoscopic Functional Luminal Impedance Probe (EndoFLIP) measures simultaneous pressure and diameter to diagnose and manage various upper gastrointestinal disorders. The distensibility index (DI) is a functional measure of how much force (mm2/mm Hg) is required to stretch open the esophagus.
Writing in Clinical Gastroenterology and Hepatology, researchers in Chicago said that previously, the extent of scar tissue in the esophagus could only be evaluated visually during endoscopy, making it challenging to detect early scarring and intervene before the damage progresses, leading to the development of esophageal rings and stricture, which can cause solid food to become impacted.
Symptoms of fibrostenosis, a complication of chronic EoE, are highly variable and may contribute to esophageal dysfunction even if the early stages are undetected on endoscopy.
The researchers analyzed a prospectively recruited group of 59 patients aged 9 to 21 years undergoing upper endoscopy and EndoFLIP for suspected or previously diagnosed EoE in order to assess whether esophageal DI can be used to define fibrostenotic severity. The DI is not affected by age in children older than 9 years, they noted.
“In pediatric EoE, the usefulness of esophageal distensibility as a clinical phenotyping tool remains unclear,” they wrote. “Further, it is unknown how esophageal distensibility in pediatric EoE relates to clinically established parameters of fibrosis, including symptoms of esophageal dysfunction, endoscopic rings, and subepithelial fibrosis on biopsy.”
Results showed the DI was significantly lower in patients with fibrotic compared with inflammatory features on endoscopy (median [IQR], 3.3 (2.3-4.4) vs 5.5 [4.1-6.0]; P = .02) and showed no correlation with eosinophil count.
The researchers were able to propose a criteria for a rigid esophagus in children with EoE, writing that a DI below 4.5 mm2/mm Hg predicted grade 2 rings on endoscopy with area under the curve (AUC) of 0.81 (P = .0004). DI predicted food impaction in both unadjusted and adjusted models (fully adjusted odds ratio, 1.44; 95% CI, 1.02-2.14; P = .0486).
“This is a gamechanger in how we care for kids with EoE,” senior author Joshua Wechsler, MD, MSCI, medical director of the Eosinophilic Gastrointestinal Diseases Program at Lurie Children’s and assistant professor of pediatrics at Northwestern University Feinberg School of Medicine, said in a statement. “Now, if distensibility is low, we can dilate the esophagus during the same procedure, and because we can pinpoint exactly where the scarring is, our intervention is more targeted and takes much less time. We are seeing improvements in symptoms, which is incredibly exciting.”
Reference
Hoffmann NV, Keeley K, Wechsler JB. Esophageal distensibility defines fibrostenotic severity in pediatric eosinophilic esophagitis. Clin Gastroenterol Hepatol. Published online September 16, 2022. doi:10.1016/j.cgh.2022.08.044
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More